Edition:
United Kingdom

Tracon Pharmaceuticals Announces Termination Of Phase 3 Tappas Trial


Friday, 12 Apr 2019 

April 12 (Reuters) - TRACON Pharmaceuticals Inc ::TRACON PHARMACEUTICALS ANNOUNCES TERMINATION OF PHASE 3 TAPPAS TRIAL BASED ON THE RECOMMENDATION OF THE INDEPENDENT DATA MONITORING COMMITTEE.TRACON PHARMACEUTICALS INC - TRIAL WAS TERMINATED FOR FUTILITY BASED ON RECOMMENDATION OF INDEPENDENT DATA MONITORING COMMITTEE.TRACON PHARMACEUTICALS INC - WILL WORK WITH INVESTIGATORS TO APPROPRIATELY CONCLUDE STUDY.TRACON PHARMACEUTICALS INC - ANTICIPATE CURRENT CASH RUNWAY WILL NOW EXTEND INTO Q3 OF 2020.TRACON PHARMACEUTICALS INC - WILL TERMINATE FURTHER ENROLLMENT IN COMPANY SPONSORED TRIALS OF TRC105 IN ONCOLOGY..TRACON PHARMACEUTICALS INC - WILL CONTINUE TO SUPPORT PARTNER, SANTEN, IN THEIR DEVELOPMENT OF DE-122 IN WET AMD.TRACON PHARMACEUTICALS INC - WILL ALSO CONTINUE TO DEVELOP OTHER DRUG CANDIDATES, INCLUDING TRC253 IN PARTNERSHIP WITH JANSSEN.TRACON PHARMACEUTICALS INC - INTEND TO ADVANCE CANDIDATES WITHIN I-MAB'S BROAD BISPECIFIC PIPELINE INTO CLINIC IN US AS EARLY AS BEGINNING OF NEXT YEAR. 

Company Quote

0.5244
 --
23 Jul 2019